GenScript Debuts AmMag™ Quatro to Revolutionize Automated Plasmid Maxi-Prep Purification
Latest innovative laboratory automation technology from GenScript is set to streamline maxi-scale plasmid purification, significantly reducing the manpower and time required to obtain high-quality, transfection-grade plasmids. During private-access testing, the AmMag Quatro system has already made remarkable contributions to cutting-edge biotech research projects, including viral vector development for cell engineering and gene therapy advancements.
PISCATAWAY, N.J., June 20, 2023 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has added the AmMag™ Quatro automated plasmid purification system to its lab and research product line-up. The system streamlines maxi-scale plasmid purification and reduces the manpower and time needed to purify high-quality, transfection-grade plasmid. Since its introduction, AmMag Quatro has been used at the forefront of biotech research, including breakthrough projects such as viral vector development for cell engineering and gene therapy.
Ensuring the availability of high-quality, transfection-ready plasmids is of paramount importance for the success of biotechnological research and development. However, traditional plasmid purification methods are highly labor-intensive, inefficient, and prone to costly human or process errors. These manual methods not only demand excessive labor and time but also impose limitations in terms of large-scale cultures, throughput, result consistency, and the risk of contamination. Consequently, plasmid purification has emerged as a significant process bottleneck at numerous laboratories.
Meanwhile, demand for high-quality, transfection-grade plasmids has skyrocketed because plasmid DNA from bacteria is an essential component of genetic engineering and other biotechnology applications, such as cloning, transfection, and gene therapy. The need for an automated, large-scale plasmid purification solution — one that can deliver superior-quality DNA with enhanced efficiency and unparalleled reproducibility, effectively addressing the shortcomings of current approaches — has become increasingly evident.
For research laboratories, the AmMag Quatro system is a game-changing addition to their arsenal of advanced equipment, offering scientists in academic, pharmaceutical and biotech settings a reliable and efficient way to purify high-quality, transfection-grade plasmids at scale; the AmMag Quatro system shortens the cycle of obtaining crucial plasmids through an efficient and expedient purification process.
The AmMag Quatro system encompasses a state-of-the-art controller capable of simultaneously operating up to four independent purification modules, along with pre-filled consumables and verified protocols. Each module can process up to six samples in one run, increasing throughput and efficiency. The system leverages magnetic bead technology and related reagents to automate the entire maxi-scale purification process, providing researchers with a reliable and efficient way to purify pDNA samples, reduce the risk of errors, and improve reproducibility.
"The AmMag Quatro has become a powerful tool for researchers to advance their work, and we are thrilled to see the impact it has had on the scientific community since its introduction," said Dr. Hong Qian, COO of the Life Science Group and general manager of GenScript Inc. Products Division.
Since its introduction, AmMag Quatro has received high praise from prominent users in the biotechnology industry, including Dr. Zhonghua Zhu, head of vector development and cell engineering at TScan Therapeutics.
"Since we started using the AmMag Quatro, our workflow has been transformed. We no longer need dedicated personnel for manual work, and we can customize the parameters for DNA prep to optimize our results. This cutting-edge system has transformed TScan's workflow, increasing efficiency and throughput," said Dr. Zhu. "We have achieved outstanding results with the AmMag Quatro. It has exceeded our expectations in terms of time and cost savings, and it has become the standard for our organization's plasmid purification needs."
Where to learn more about the GenScript AmMag Quatro system
Visit the AmMag Quatro product page
Download the brochure and watch the AmMag Quatro video
Watch the AmMag Quatro webinar: Break the Bottleneck
About GenScript Biotech Corporation
GenScript Biotech Corporation (HK:1548) is the world's leading technology and service provider of life-science R&D and manufacture. Built upon its solid gene synthesis technology, GenScript Biotech is divided into four major platforms: the life-science service and product platform, the biologics contract development and manufacturing organization (CDMO) platform, the industrial synthetic products platform, and the integrated global cell therapy platform.
GenScript Biotech was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript Biotech's business operations span over 100 countries and regions worldwide with legal entities located in the US, Mainland China, Hong Kong, China, Japan, Singapore, Netherlands, Ireland, the United Kingdom, Korea, and Belgium. GenScript Biotech provides premium, convenient and reliable services and products for over 200,000 customers.
As of December 31, 2022, GenScript Biotech had more than 6,000 employees globally, over 37% of whom hold master's and/or Ph.D. degrees. In addition, GenScript Biotech owns a number of intellectual property rights, including over 210 patents, over 800 pending patent applications and great numbers of trade secrets.
Driven by the corporate mission of "make people and nature healthier through biotechnology," GenScript Biotech strives to become the most trustworthy biotech company in the world. As of December 31, 2022, 76,000 peer-reviewed journal articles worldwide have cited GenScript Biotech's services and products. For more information, please visit GenScript Biotech's official website genscript.com.
Media contact:
Tim Cox — ZingPR for GenScript
tim@zingpr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genscript-debuts-ammag-quatro-to-revolutionize-automated-plasmid-maxi-prep-purification-301854804.html
SOURCE GenScript Biotech Corporation
